Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last $32.45 USD
Change Today +1.26 / 4.04%
Volume 2.3M
ALKS On Other Exchanges
As of 8:10 PM 02/12/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Connaught House

1 Burlington Road

Dublin, 4


Phone: 353 1 772 8000


Alkermes Public Limited Company operates as an integrated biopharmaceutical company worldwide. The company has a portfolio of approximately 20 marketed products and a clinical pipeline of product candidates that address central nervous system disorders, such as addiction, schizophrenia and depression. Products Marketed Products RISPERDAL CONSTA and INVEGA SUSTENNA/XEPLION RISPERDAL CONSTA (risperidone long-acting injection) and INVEGA SUSTENNA/XEPLION (paliperidone palmitate extended-release injectable suspension) are long-acting atypical antipsychotics that incorporate the company’s proprietary technologies and are marketed and sold by of Janssen (Janssen Pharmaceutica N.V. (together with Janssen Pharmaceutica Inc.; Janssen Pharmaceutica International, a division of Cilag International AG; and their affiliates, collectively ‘Janssen’)). RISPERDAL CONSTA is approved in the U.S. for the treatment of schizophrenia and as both monotherapy and adjunctive therapy to lithium or valproate in the maintenance treatment of bipolar I disorder. RISPERDAL CONSTA is approved in various countries outside of the U.S. for the treatment of schizophrenia and the maintenance treatment of bipolar I disorder. RISPERDAL CONSTA uses the company’s polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through just one injection every two weeks. RISPERDAL CONSTA is manufactured by the company and marketed and sold by Janssen worldwide. INVEGA SUSTENNA is approved in the U.S. for the acute and maintenance treatment of schizophrenia, and as of November 2014, for the treatment of schizoaffective disorder as either a monotherapy or adjunctive therapy. Paliperidone palmitate extended-release injectable suspension is approved in the European Union (EU) and other countries worldwide for the treatment of schizophrenia and is marketed and sold under the trade name XEPLION. INVEGA SUSTENNA uses the company’s nanoparticle injectable extended-release technology to increase the rate of dissolution and enable the formulation of an aqueous suspension for once-monthly intramuscular administration. INVEGA SUSTENNA/XEPLION is manufactured and commercialized worldwide by Janssen. AMPYRA/FAMPYRA AMPYRA/FAMPYRA is the first treatment approved in the U.S. and in approximately 50 countries across Europe, Asia, and the Americas to improve walking in adults with MS (multiple sclerosis) who have walking disability, as demonstrated by an increase in walking speed. Extended-release dalfampridine tablets are marketed and sold by Acorda Therapeutics, Inc. (Acorda) in the U.S. under the trade name AMPYRA and by Biogen Idec International GmbH outside the U.S. under the trade name FAMPYRA. AMPYRA and FAMPYRA incorporate the company’s oral controlled-release technology. AMPYRA and FAMPYRA are manufactured by the company. BYDUREON BYDUREON (exenatide extended-release for injectable suspension) is approved in the U.S. and the EU for the treatment of type 2 diabetes. In February 2014, AstraZeneca plc (AstraZeneca) assumed sole responsibility for the development and commercialization of BYDUREON. BYDUREON, a once-weekly formulation of exenatide, the active ingredient in BYETTA, uses the company’s polymer-based microsphere injectable extended-release technology. In September 2014, AstraZeneca announced that the once-weekly BYDUREON Pen 2 mg, which is a pre-filled, single-use pen injector that contains the same formulation and dose as the original BYDUREON single-dose tray, was available by prescription in pharmacies in the U.S. AstraZeneca stated that it received a positive opinion from the Committee for Medicinal Products for Human Use on the BYDUREON dual-chamber pen and that it filed for approval of the dual-chamber pen in Japan in April 2014. VIVITROL VIVITROL is a once-monthly injectable medication approved in the U.S. and Russia for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. VIVITROL uses the company’s polymer-based microsphere injectable extended-release technology to deliver and ma


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALKS:US $32.45 USD +1.26

ALKS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $16.07 USD 0.00
Emergent BioSolutions Inc $35.88 USD +0.68
Impax Laboratories Inc $30.89 USD +0.16
Jazz Pharmaceuticals PLC $113.78 USD +1.06
Pacira Pharmaceuticals Inc/DE $57.04 USD +0.76
View Industry Companies

Industry Analysis


Industry Average

Valuation ALKS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.3x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.6x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ALKERMES PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at